Cautious FDA Is Obstacle For Burgeoning Diabetes Device Market
Executive Summary
Is innovation in the diabetes device market being hampered by a slowdown in FDA approvals? That question was the unofficial, under-riding theme at the American Diabetes Association 71st Scientific Sessions in June.
You may also be interested in...
The Artificial Pancreas: A Race To The Finish
The first fully functional artificial pancreas for patients with diabetes could be ready for regulatory submission in the next few years. Medtronic has achieved notable success in this area to date, but positive clinical studies have put J&J in a good position as well, and the medical community is watching closely as the major developments in this groundbreaking endeavor continue to move forward.
The Artificial Pancreas: A Race To The Finish
The race to develop a fully functional artificial pancreas for patients with diabetes is entering the later stages, and the first such device could be ready for regulatory submission in the next few years. Medtronic has achieved notable success in this area to date, but positive clinical studies have put J&J in a good position as well, and the medical community is watching closely as the major developments in this groundbreaking endeavor continue to move forward.
Tight Glycemic Control: Critical Care’s Balancing Act
Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving patient outcomes. Today, a small pack of companies is trying to finally deliver on the promise.